Effect of silymarin supplement on the pharmacokinetics of rosuvastatin

Pharmaceutical Research

Volumn 25, Issue 8, 2008, Pages 1807-1814

  Deng, Jian Wei ^a,c   Shon, Ji Hong ^a,b   Shin, Ho Jung ^a   Park, Soo Jin ^a   Yeo, Chang Woo ^a,b   Zhou, Hong Hao ^a,c   Song, Im Sook ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BCRP; OATP1B1; Pharmacokinetics; Rosuvastatin; Silymarin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; LEGALON 140; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PLACEBO; ROSUVASTATIN; SILYMARIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG TRANSPORT; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ALGORITHMS; ANTIOXIDANTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; SILYMARIN; SULFONAMIDES;

EID: 46749154716     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9492-0     Document Type: Article

References (30)

1. J. Kuhnau. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet. 24:117-191 (1976).
2. D. Lorenz, P. W. Lucker, W. H. Mennicke, and N. Wetzelsberger. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp. Clin. Pharmacol. 6:655-661 (1984).
3. K. E. Mayer, R. P. Myers, and S. S. Lee. Silymarin treatment of viral hepatitis: a systematic review. J. Viral. Hepat. 12:559-567 (2005).
4. K. R. Ball, and K. V. Kowdley. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J. Clin. Gastroenterol. 39:520-528 (2005).
5. X. Wang, A. W. Wolkoff, and M. E. Morris. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos. 33:1666-1672 (2005).
6. H. C. Cooray, T. Janvilisri, H. W. van Veen, S. B. Hladky, and M. A. Barrand. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317:269-275 (2004).
7. S. Zhang, X. Yang, and M. E. Morris. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65:1208-1216 (2004).
8. S. Zhang, X. Yang, and M. E. Morris. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21:1263-1273 (2004).
9. S. Zhang, X. Wang, K. Sagawa, and M. E. Morris. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos. 33:341-348 (2005).
10. G. Conseil, H. Baubichon-Cortay, G. Dayan, J. M. Jault, D. Barron, and A. Di Pietro. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 95:9831-9836 (1998).
11. E. M. Leslie, Q. Mao, C. J. Oleschuk, R. G. Deeley, and S. P. Cole. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 59:1171-1180 (2001).
12. S. Zhang, and M. E. Morris. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm. Res. 20:1184-1191 (2003).
13. M. J. Chapman, and F. McTaggart. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. 2:33-36 (2002)discussion 36-37.
14. R. Paoletti, M. Fahmy, G. Mahla, J. Mizan, and H. Southworth. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk 8:383-890 (2001).
15. D. W. Schneck, B. K. Birmingham, J. A. Zalikowski, P. D. Mitchell, Y. Wang, P. D. Martin, K. C. Lasseter, C. D. Brown, A. S. Windass, and A. Raza. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75:455-463 (2004).
16. R. H. Ho, R. G. Tirona, B. F. Leake, H. Glaeser, W. Lee, C. J. Lemke, Y. Wang, and R. B. Kim. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806 (2006).
17. L. Huang, Y. Wang, and S. Grimm. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab. Dispos. 34:738-742 (2006).
18. Y. Imai, M. Nakane, K. Kage, S. Tsukahara, E. Ishikawa, T. Tsuruo, Y. Miki, and Y. Sugimoto. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1:611-616 (2002).
19. W. Zhang, B. N. Yu, Y. J. He, L. Fan, Q. Li, Z. Q. Liu, A. Wang, Y. L. Liu, Z. R. Tan, F. Jiang, Y. F. Huang, and H. H. Zhou. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373:99-103 (2006).
20. M. K. Pasanen, H. Fredrikson, P. J. Neuvonen, and M. Niemi. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 10.1038/sj.clpt.6100220 (2007).
21. J. H. Choi, M. G. Lee, J. Y. Cho, J. E. Lee, K. H. Kim, K. Park. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 10.1038/sj.clpt.6100267 (2007).
22. H. Kusuhara, T. Sekine, N. Utsunomiya-Tate, M. Tsuda, R. Kojima, S. H. Cha, Y. Sugiyama, Y. Kanai, and H. Endou. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274:13675-13680 (1999).
23. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33:434-439 (2005).
24. E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62:5035-5040 (2002).
25. Y. Shitara, and Y. Sugiyama. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112:71-105 (2006).
26. P. J. Neuvonen, M. Niemi, and J. T. Backman. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80:565-581 (2006).
27. Y. C. Kim, E. J. Kim, E. D. Lee, J. H. Kim, S. W. Jang, Y. G. Kim, J. W. Kwon, W. B. Kim, and M. G. Lee. Comparative bioavailability of silibinin in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 41:593-596 (2003).
28. D. Savio, P. C. Harrasser, and G. Basso. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin. Arzneimittelforschung 48:1104-1106 (1998).
29. H. U. Schulz, M. Schurer, G. Krumbiegel, W. Wachter, R. Weyhenmeyer, and G. Seidel. The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung 45:61-64 (1995).
30. F. Q. Li, and J. H. Hu. Improvement of the dissolution rate of silymarin by means of solid dispersions. Chem. Pharm. Bull. (Tokyo) 52:972-973 (2004).